Marksans Pharma Ltd (MARKSANS)
₹205.24▲9.63%
Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Marksans Pharma Ltd. An average target of ₹215
Source: S&P Global Market Intelligence
Marksans Pharma Ltd Share analysis
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹184.45₹207.5552 Week's Low
52 Week's High
₹97.45₹207.55
| Returns % | |
| 1 Month Return | + 13.47 % |
| 3 Month Return | + 11.34 % |
| 1 Year Return | + 77.29 % |
| Market Stats | |
| Previous Close | ₹187.22 |
| Open | ₹184.45 |
| Volume | 78.87L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹8,484.13Cr |
Key Statistics
| P/E Ratio | 27.02 |
| PEG Ratio | 64.32 |
| Market Cap | ₹8,484.13 Cr |
| P/B Ratio | 2.87 |
| EPS | 1.97 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹8,484.13 Cr | 202.22% | 0.50 | ₹265 Cr | ₹1,852 Cr |
 | NA | ₹17.18 Cr | -6.84% | 0.50 | -₹3 Cr | ₹45 Cr |
| NA | ₹164.28 Cr | 90.19% | 0.58 | NA | NA |
 | NA | ₹1,131.02 Cr | 120.9% | 0.54 | ₹27 Cr | ₹550 Cr |
| NA | ₹14.76 Cr | 80.9% | 0.69 | NA | NA |
Company Information
Share Price: ₹205.24 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹8,484.13Cr as of today
Revenue: ₹560.01Cr as on March 2024 (Q1 24)
Net Profit: ₹77.64Cr as on March 2024 (Q1 24)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
| Organisation | Marksans Pharma Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Marksans Pharma Ltd
Marksans Pharma Ltd Reports Increase in FII/FPI Holding and Revenue Growth - 17 Jul, 2024
In Q1FY25, FII/FPI increased their holding in Marksans Pharma Limited by 3.02%. The company's revenue from operations grew by 17.56% from FY23 to FY24, accompanied by profits of Rs. 265 Crores to Rs. 315 Crores.
Marksans Pharma Shows Robust Financial Performance - 05 Jul, 2024
Marksans Pharma reports a significant increase in annual revenue to INR 22.28 billion, with an earnings forecast of a 21.63% increase per year. Insiders have increased their holdings, signaling confidence amidst strategic expansions and operational enhancements. Recent dividend increase to INR 0.60 per share.
Marksans Pharma's Subsidiary Receives Marketing Approval for Two Products - 02 Jul, 2024
Relonchem Ltd., a wholly owned subsidiary of Marksans Pharma, has received marketing authorization from the UK regulator for two products - Rasagiline Relonchem and Olmesartan film-coated tablets used to treat Parkinson's disease and hypertension.
Insights on Marksans Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 1 month, MARKSANS stock has moved up by 13.5%
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 43.85% to 43.87% in Jun 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 4.69% to 7.71% in Jun 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 9.4%
- NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 87.2% return, outperforming this stock by 9.9%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 4.23% to 2.82% in Jun 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 35.40% to 33.78% in Jun 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 590.93 Cr → 576.54 Cr (in ₹), with an average decrease of 2.4% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 83.52 Cr → 78.29 Cr (in ₹), with an average decrease of 3.1% per quarter
Company Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹560.01Cr | ↓4.46% |
Net Income | ₹77.64Cr | ↓6.42% |
Net Profit Margin | 13.86% | ↓2.12% |
| 2023 | Y/Y Change | |
|---|---|---|
Revenue | ₹1,852.14Cr | ↑24.23% |
Net Income | ₹265.32Cr | ↑42.03% |
Net Profit Margin | 14.33% | ↑14.37% |
| 2023 | Y/Y Change | |
|---|---|---|
Total Assets | ₹1,346.73Cr | ↑39.34% |
Total Liabilities | ₹235.40Cr | ↑29.47% |
| 2023 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | ₹51.73Cr | ↓7.58% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.87% | 0.06 | |
| Foreign Institutions | 7.71% | 64.49 | |
| Mutual Funds | 2.81% | ||
| Retail Investors | 33.78% | ||
| Others | 11.82% |
Key Indicators
Marksans Pharma Ltd Valuation
Marksans Pharma Ltd in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (27.02x)
July 23, 2024
Industry (56.07x)
July 23, 2024
Highest (46.60x)
January 24, 2018
Earnings and Dividends
Marksans Pharma Ltd Earnings Results
Marksans Pharma Ltd’s net profit fell -4.44% since last year same period to ₹78.29Cr in the Q4 2023-2024. On a quarterly growth basis, Marksans Pharma Ltd has generated -5.95% fall in its net profits since last 3-months.
Read More about Earnings ResultsMarksans Pharma Ltd Dividends May,2023
In the quarter ending March 2023, Marksans Pharma Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.37%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Marksans Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Marksans Pharma Ltd shares.
Marksans Pharma Ltd (MARKSANS) share price today is ₹205.24
Marksans Pharma Ltd is listed on NSE
Marksans Pharma Ltd is listed on BSE
- Today’s highest price of Marksans Pharma Ltd is ₹207.55.
- Today’s lowest price of Marksans Pharma Ltd is ₹184.45.
PE Ratio of Marksans Pharma Ltd is 27.02
PE ratio = Marksans Pharma Ltd Market price per share / Marksans Pharma Ltd Earnings per share
Today’s traded volume of Marksans Pharma Ltd(MARKSANS) is 78.87L.
Today’s market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹8484.13Cr.
| Marksans Pharma Ltd(MARKSANS | Price |
|---|---|
52 Week High | ₹207.55 |
52 Week Low | ₹97.45 |
Marksans Pharma Ltd(MARKSANS) share price is ₹205.24. It is down -1.11% from its 52 Week High price of ₹207.55
Marksans Pharma Ltd(MARKSANS) share price is ₹205.24. It is up 110.61% from its 52 Week Low price of ₹97.45
| Marksans Pharma Ltd(MARKSANS | Returns |
|---|---|
1 Day Returns | 18.02% |
1 Month Returns | 13.47% |
3 Month Returns | 11.34% |
1 Year Returns | 77.29% |